3 Biotech Stocks Trending This Week

The number mergers and acquisitions in the biotech sector has started to move closer to that of all-time highs of 2016. Last year, M&A deals in the sector totaled around $200 billion, led by deals from heavyweights Johnson & Johnson’s (JNJ) and Gilead Science (GILD). Analysts remain confident that this year should only exceed those numbers.


This year has already started with a bang, as Big Pharma continues to hunt for profitable acquisitions to beef up their pipelines. In January, top dog biotech Celgene (CELG) and pharma titan Sanofi (SNY) announced two multi-billion-dollar acquisitions. Pressure on Big Pharma continues to heat up with the consolidation throughout the sector, as payers unite, and Amazon (AMZN)makes their way into the space.

Developing fresh research and development projects takes significant time and money, so these large drug makers continue to search for smaller companies with innovative candidates. Despite the recent market volatility, there are several small cap biotech stocks that investors, and Big Pharma, may be watching for what is in their pipelines.

Notable Mention:

Today Emergent BioSolutions (EBS) announced acquisition of Adapt Pharma for up to $735M. Adapt markets Opiant Pharmaceutical’s (OPNT) drug NARCAN. This news sent its stock price up nearly 200% during premarket trading.

Click Here For Top Biotech Stocks Gaining Investor Attention.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s